UAE Approves Foundayo Oral Weight Loss Pill: GLP-1 Alternative to Injections
A new oral medication for weight loss has been approved in the UAE, offering patients an alternative to injectable treatments. The drug, known as Foundayo (orforglipron), has been cleared by the Emirates Drug Establishment (EDE) and is expected to be available from May 2026, marking a significant step in the country’s fight against obesity. A new option for patients.
Developed by global pharmaceutical company Eli Lilly, the once-daily pill belongs to a class of medicines called GLP-1 receptor agonists. These drugs work by regulating appetite and reducing food intake, helping individuals manage their weight more effectively. Unlike many existing treatments, this medication does not require injections and can be taken without strict food or water restrictions, making it a more convenient option for patients. Convenience meets science.
Doctors have emphasized, however, that the new pill is not meant for general use or casual weight loss. It will only be prescribed under medical supervision and is intended primarily for adults diagnosed with obesity. Eligibility is typically based on body mass index (BMI). Patients with a BMI of 30 or higher may qualify, as well as those with a BMI above 27 who also suffer from related health conditions such as type 2 diabetes, high blood pressure, high cholesterol, sleep apnea, or joint issues. Not for casual use.
Medical experts note that the drug may also be considered for individuals who have struggled to lose weight through diet and exercise alone. However, it will generally be prescribed by specialists such as endocrinologists or internal medicine doctors, especially during the initial stages. These professionals are responsible for assessing a patient’s medical history, identifying any potential risks, and monitoring side effects throughout the treatment. Specialist oversight required.
Before starting the medication, patients will need to undergo a comprehensive health evaluation. This includes measuring BMI, checking blood sugar levels, reviewing cholesterol profiles, and assessing liver, kidney, and thyroid function. Doctors may also examine personal and family medical history to ensure the treatment is safe and appropriate. Thorough evaluation needed.
Despite its promise, the drug is not suitable for everyone. It is not recommended for individuals with certain thyroid cancers or rare endocrine disorders, nor for pregnant or breastfeeding women. Patients with severe gastrointestinal or kidney issues may also require careful evaluation before being considered for the treatment. Not for everyone.
Importantly, healthcare professionals stress that this medication is not a quick fix. Treatment is expected to be long-term and, in some cases, may continue for life depending on how well the patient responds. Stopping the drug without maintaining healthy habits could lead to weight regain, highlighting the importance of sustained lifestyle changes. A long-term commitment.
Experts also underline that the pill is designed to complement—not replace—healthy living. Patients will still need to follow a balanced diet and engage in regular physical activity to achieve meaningful and lasting results. A tool, not a miracle.
The approval of Foundayo places the UAE among the first countries globally to introduce this next-generation obesity treatment. With obesity linked to more than 200 health conditions, including heart disease and diabetes, authorities see this as a major step toward improving public health outcomes and expanding access to innovative therapies. A global first.
Overall, while the new pill offers a more convenient approach to weight management, its success will depend on careful medical supervision and a long-term commitment to healthier lifestyle choices. The future of obesity treatment is here. Patients have a new option.
